InnoSino Biopharma
Overview
Mermaid diagram (expand to render)
InnoSino Biopharma is a Shanghai-based biotechnology company developing innovative therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease (PD) and Alzheimer's disease (AD). Founded in 2015, InnoSino has established itself as a leading Chinese biotech focused on protein-targeting approaches including monoclonal antibodies and small molecule inhibitors that address the underlying pathological mechanisms of neurodegeneration.
The company's name "InnoSino" reflects its dual identity—"Inno" represents innovation in biotechnology, while "Sino" indicates its Chinese heritage and commitment to advancing neuroscience research in China. InnoSino operates from state-of-the-art research facilities in the Shanghai Zhangjiang Hi-Tech Park, one of China's premier biotechnology hubs, with additional operations in the Suzhou Industrial Park["程建军2024"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Shanghai, China |
| Founded | 2015 |
| Focus | Small molecule drugs, immunotherapy |
| Employees | ~120 (as of 2024) |
| Stage | Clinical (Phase 1) |
InnoSino benefits from its strategic location in the Yangtze River Delta, one of China's most developed biopharmaceutical clusters. The company maintains close relationships with leading Chinese academic institutions including Fudan University, Shanghai Institute of Materia Medica (SIMM), and the Chinese Academy of Sciences.
Therapeutic Focus
Alpha-Synuclein Targeting
InnoSino's primary therapeutic approach targets alpha-synuclein (α-syn), the protein that forms the characteristic Lewy bodies found in the brains of Parkinson's disease patients[@spillantini2000; @braak2003]. The company's innovative platform addresses both antibody-based and small molecule approaches to α-syn pathology:
Monoclonal antibodies: Development of antibodies that recognize pathological α-syn aggregates while sparing physiological monomeric forms
Small molecule inhibitors: Discovery of compounds that prevent α-syn aggregation or promote clearance of existing aggregates
RNAi approaches: Gene silencing strategies to reduce α-syn expressionThe rationale for α-syn targeting is strong, as aggregation of this protein into toxic oligomers and fibrils is central to PD pathogenesis and correlates with disease progression[@mccann2016].
LRRK2 Inhibition
In addition to α-syn approaches, InnoSino is developing inhibitors of leucine-rich repeat kinase 2 (LRRK2), a protein kinase that has been genetically linked to both familial and sporadic Parkinson's disease. Pathogenic LRRK2 mutations cause increased kinase activity, leading to disruptions in cellular processes including autophagy, lysosomal function, and synaptic transmission[@berman2018].
Tau Pathology
The company has also expanded into Alzheimer's disease through development of anti-tau antibodies and phosphorylation inhibitors. Tau pathology represents a complementary target to amyloid-based approaches, with tau neurofibrillary tangles correlating more closely with cognitive decline than amyloid plaques.
Neuroinflammation
InnoSino recognizes the critical role of neuroinflammation in neurodegenerative disease progression and has established programs targeting microglial modulation and anti-inflammatory pathways[@heneka2015].
Pipeline
ISB-101: Anti-Alpha-Synuclein Antibody
ISB-101 is InnoSino's lead clinical candidate—a monoclonal antibody designed to selectively bind pathological alpha-synuclein species.
Mechanism of Action
ISB-101 targets a conformation-specific epitope present on aggregated α-syn but not on normal monomeric protein. This selective targeting enables:
- Recognition of Lewy bodies and Lewy neurites
- Binding to extracellular α-syn that may propagate between neurons
- Fc-mediated clearance through immune effector functions
The antibody was generated using the company's proprietary platform combining phage display library screening and humanization techniques.
Clinical Development
- Phase I: First-in-human study in healthy volunteers (completed)
- Phase Ib: Multiple ascending dose in early PD patients (ongoing)
- Phase II: Planned for 2026
The Phase I study demonstrated favorable safety and pharmacokinetic profiles, with dose-proportional exposure and target engagement as measured by cerebrospinal fluid biomarkers.
Clinical Endpoints
The Phase Ib study is evaluating:
- Safety and tolerability in PD patients
- CSF α-synuclein levels as a pharmacodynamic marker
- PET imaging using α-syn-specific tracers (in collaboration with academic partners)
- Motor and cognitive outcomes
ISB-202: LRRK2 Inhibitor
ISB-202 is InnoSino's small molecule LRRK2 inhibitor program, currently in IND-enabling studies.
Mechanism
LRRK2 inhibitors work by:
- Reducing LRRK2 kinase activity
- Decreasing downstream phosphorylation events
- Improving lysosomal function
- Potentially reducing α-syn toxicity
The compound has demonstrated excellent brain penetration in preclinical models, with target engagement confirmed at doses achieving plasma concentrations below the no-observed-adverse-effect level (NOAEL).
Preclinical Results
- Significant reduction in LRRK2 autophosphorylation in brain tissue
- Improved performance in α-syn transgenic mouse models
- No cardiotoxicity (a known class effect of some LRRK2 inhibitors)
- Favorable ADME properties
ISB-301: Anti-Tau Antibody
ISB-301 is InnoSino's Alzheimer's disease program, an antibody targeting pathological tau species.
Development Status
- Discovery: Completed
- Lead optimization: Ongoing
- IND-enabling: Projected 2027
Antibody Discovery
InnoSino has established a comprehensive antibody discovery platform:
Phage display libraries: Human naive and immune libraries for antibody discovery
Single B cell sorting: Direct cloning of antigen-specific B cells from immunized animals
Humanization: Rapid conversion of rodent antibodies to human frameworks
Affinity maturation: Engineering for improved binding kineticsSmall Molecule Chemistry
The company's medicinal chemistry team maintains:
- Structure-based drug design capabilities
- High-throughput screening infrastructure
- In-house animal models for PK/PD correlation
- CNS drug delivery expertise
Biomarker Development
InnoSino has invested significantly in biomarker development to support patient selection and clinical endpoints:
- CSF α-synuclein assays (total, phosphorylated, oligomeric)
- PET tracers for α-syn and tau
- Blood-based biomarkers for disease monitoring
Collaborations
Academic Partnerships
InnoSino maintains research collaborations with leading Chinese institutions:
- Fudan University: Neuroscience research and clinical trials
- Shanghai Institute of Materia Medica (SIMM): Drug discovery and pharmacology
- Chinese Academy of Sciences: Basic research and target validation
- Shanghai Jiao Tong University: Translational medicine
Industry Partnerships
- WuXi Biologics: Manufacturing for clinical supply
- Thermo Fisher Scientific: Assay development and reagents
- Eurofins: GLP toxicology studies
- IQVIA: Clinical operations support
International Expansion
InnoSino is strategically establishing international presence:
- US operations: Subsidiary in Cambridge, Massachusetts for FDA interactions
- European partnerships: Discussions with EU biotech for co-development
- Japan regulatory: Consultations with PMDA
Competitive Landscape
InnoSino competes with several global companies in the Parkinson's disease immunotherapy space:
| Company | Product | Mechanism | Status |
|---------|---------|-----------|--------|
| Roche/Genentech | Prasinezumab | Anti-α-syn antibody | Phase II |
| Biogen | BIIB054 | Anti-α-syn antibody | Phase II |
| Prothelia | PRX002 | Anti-α-syn antibody | Phase II |
| Alector | AL001 | Progranulin modulator | Phase II |
| InnoSino | ISB-101 | Anti-α-syn antibody | Phase I |
InnoSino differentiates through:
- Novel epitope targeting (potentially superior efficacy)
- Strong presence in Chinese market
- Integrated antibody and small molecule platforms
Funding and Financial History
| Round | Year | Amount | Lead Investors |
|-------|------|--------|----------------|
| Series A | 2015 | $8M | Sinopharm Capital, ZhenFund |
| Series B | 2018 | $25M | Qiming Venture, Hillhouse Capital |
| Series C | 2022 | $45M | Hillhouse Capital, Sequoia China |
| Series D | 2024 | $30M | GIC, Source Code Capital |
Total raised: $108M
Future Directions
InnoSino's long-term strategy includes:
Clinical advancement: Continue ISB-101 through Phase II development
Pipeline expansion: Advance ISB-202 to IND and ISB-301 to IND-enabling
Global development: Establish international clinical trial network
Combination approaches: Explore α-syn targeting with LRRK2 inhibition
Business development: Seek partnership for US/EU commercializationSee Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein Pathology](/proteins/alpha-synuclein)
- [LRRK2 Gene](/genes/lrrk2)
- [Chinese Biotechnology Companies](/companies/chinese-biotech-overview)
- [Monoclonal Antibodies for Neurodegeneration](/therapeutics/monoclonal-antibodies)
References
[InnoSino Corporate Website (2024)](https://www.innosino.com)
[Kalia LV, Lang AE, Parkinson's disease (2015)]([DOI:10.1016/S0140-6736(14)60193-8](https://doi.org/10.1016/S0140-6736(14)60193-8))
[Spillantini MG, et al., Alpha-synuclein in Lewy bodies (2000)](https://doi.org/10.1038/35037610)
[Braak H, et al., Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://doi.org/10.1007/s00401-003-0568-y)
[Berman SB, et al., LRRK2: Function and dysfunction in Parkinson's disease (2018)](https://doi.org/10.1016/j.neuropharm.2018.01.023)
[McCann H, et al., Alpha-synuclein and Lewy body pathology in Parkinson's disease (2016)](https://doi.org/10.1002/mds.26521)
[Heneka MT, et al., Neuroinflammation in Alzheimer's disease (2015)]([DOI:10.1016/S1474-4422(15)70016-5](https://doi.org/10.1016/S1474-4422(15)70016-5))
[程建军等, 中国生物医药产业发展报告2024 (2024)]([中国医药创新促进会](https://www.cphiic.com))